Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7758-7769

  German, Nadezhda ^a   Decker, Ann M ^a   Gilmour, Brian P ^a   Gay, Elaine A ^a   Wiley, Jenny L ^a   Thomas, Brian F ^a   Zhang, Yanan ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 3 {3 [6 (PYRROLIDIN 1 YL)PYRIDIN 2 YL]PHENYL}UREA; 2 (3 NITROPHENYL) 6 (PYRROLIDINE 1 YL)PYRIDINE; 2 AMINOPYRIDINE; 2 BROMO 6 (PIPERIDIN 1 YL)PYRIDINE; 2 BROMO 6 (PYRROLIDIN 1 YL)PYRIDINE; 6 BROMO N BUTYLPYRIDIN 2 AMINE; 6 BROMO N CYCLOPENTYLPYRIDIN 2 AMINE; 6 BROMO N ETHYLPYRIDIN 2 AMINE; 6 BROMO N HEXYLPYRIDIN 2 AMINE; 6 BROMO N METHYLPYRIDIN 2 AMINE; 6 BROMO N PENTYLPYRIDIN 2 AMINE; 6 BROMO N PROPYLPYRIDIN 2 AMINE; 6 BROMO N,N DIBUTYLPYRIDIN 2 AMINE; 6 BROMO N,N DIETHYLPYRIDIN 2 AMINE; 6 BROMO N,N DIMETHYLPYRIDIN 2 AMINE; 6 BROMO N,N DIPROPYLPYRIDIN 2 AMINE; CANNABINOID 1 RECEPTOR; N (6 BROMOPYRIDIN 2 YL)ACETAMIDE; N BUTYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N ETHYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N HEXYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N METHYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N PENTYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N PROPYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N [6 (3 NITROPHENYL)PYRIDIN 2 YL]ACETAMIDE; N,N DIBUTYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N,N DIMETHYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; N,N DIPROPYL 6 (3 NITROPHENYL)PYRIDINE 2 AMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; 1-(4-CHLOROPHENYL)-3-(3-(6-PYRROLIDIN-1-YLPYRIDIN-2-YL)PHENYL)UREA; CALCIUM; CANNABINOID 2 RECEPTOR; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ALKYLATION; ALLOSTERISM; ARTICLE; BINDING ASSAY; CALCIUM MOBILIZATION; CALCIUM MOBILIZATION ASSAY; CHO CELL LINE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; IC50; METABOLISM;

ALLOSTERIC REGULATION; CALCIUM; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; PHENYLUREA COMPOUNDS; PYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907450536     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501042u     Document Type: Article

References (43)

1. Pertwee, R. G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids AAPS J. 2005, 7, E625-E654
2. Howlett, A. C.; Breivogel, C. S.; Childers, S. R.; Deadwyler, S. A.; Hampson, R. E.; Porrino, L. J. Cannabinoid physiology and pharmacology: 30 years of progress Neuropharmacology 2004, 47 (Suppl. 1) 345-358
3. Pertwee, R. G. Cannabinoid pharmacology: the first 66 years Br. J. Pharmacol. 2006, 147 (Suppl. 1) S163-S171
4. Jagerovic, N.; Hernandez-Folgado, L.; Alkorta, I.; Goya, P.; Martin, M. I.; Dannert, M. T.; Alsasua, A.; Frigola, J.; Cuberes, M. R.; Dordal, A.; Holenz, J. Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides Eur. J. Med. Chem. 2006, 41, 114-120
5. Mackie, K. Cannabinoid receptors as therapeutic targets Annu. Rev. Pharmacol. Toxicol. 2006, 46, 101-122
6. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 2006, 58, 389-462
7. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discovery 2008, 7, 438-455
8. Makriyannis, A. 2012 Division of Medicinal Chemistry Award Address. Trekking the cannabinoid road: a personal perspective J. Med. Chem. 2014, 57, 3891-3911
9. Muccioli, G. G.; Lambert, D. M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors Curr. Med. Chem. 2005, 12, 1361-1394
10. Jagerovic, N.; Fernandez-Fernandez, C.; Goya, P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications Curr. Top. Med. Chem. 2008, 8, 205-230
11. Moreira, F. A.; Grieb, M.; Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 133-144
12. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc. London, Ser. B 2012, 367, 3353-3363
13. Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery J. Med. Chem. 2012, 55, 1445-1464
14. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 2010, 62, 265-304
15. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing Pharmacol. Rev. 2002, 54, 323-374
16. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54
17. Shore, D. M.; Baillie, G. L.; Hurst, D. H.; Navas, F., III; Seltzman, H. H.; Marcu, J. P.; Abood, M. E.; Ross, R. A.; Reggio, P. H. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling J. Biol. Chem. 2014, 289, 5828-5845
18. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat. Rev. Drug Discovery 2002, 1, 198-210
19. Bridges, T. M.; Lindsley, C. W. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 2008, 3, 530-541
20. Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. I. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 2009, 156, 1178-1184
21. Pamplona, F. A.; Ferreira, J.; Menezes de Lima, O., Jr.; Duarte, F. S.; Bento, A. F.; Forner, S.; Villarinho, J. G.; Bellocchio, L.; Wotjak, C. T.; Lerner, R.; Monory, K.; Lutz, B.; Canetti, C.; Matias, I.; Calixto, J. B.; Marsicano, G.; Guimaraes, M. Z.; Takahashi, R. N. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21134-21139
22. Bauer, M.; Chicca, A.; Tamborrini, M.; Eisen, D.; Lerner, R.; Lutz, B.; Poetz, O.; Pluschke, G.; Gertsch, J. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors J. Biol. Chem. 2012, 287, 36944-36967
23. Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R. G.; Ross, R. A. Allosteric modulation of the cannabinoid CB1 receptor Mol. Pharmacol. 2005, 68, 1484-1495
24. Horswill, J. G.; Bali, U.; Shaaban, S.; Keily, J. F.; Jeevaratnam, P.; Babbs, A. J.; Reynet, C.; Wong Kai In, P. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats Br. J. Pharmacol. 2007, 152, 805-814
25. Ross, R. A. Allosterism and cannabinoid CB(1) receptors: the shape of things to come Trends Pharmacol. Sci. 2007, 28, 567-572
26. Ross, R. A. Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor Br. J. Pharmacol. 2007, 152, 565-566
27. Ahn, K. H.; Mahmoud, M. M.; Kendall, D. A. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation J. Biol. Chem. 2012, 287, 12070-12082
28. Ahn, K. H.; Mahmoud, M. M.; Samala, S.; Lu, D.; Kendall, D. A. Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor J. Neurochem. 2013, 124, 584-589
29. Wang, X.; Horswill, J. G.; Whalley, B. J.; Stephens, G. J. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum Mol. Pharmacol. 2011, 79, 758-767
30. Baillie, G. L.; Horswill, J. G.; Anavi-Goffer, S.; Reggio, P. H.; Bolognini, D.; Abood, M. E.; McAllister, S.; Strange, P. G.; Stephens, G. J.; Pertwee, R. G.; Ross, R. A. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity Mol. Pharmacol. 2013, 83, 322-338
31. Fay, J. F.; Farrens, D. L. A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569 J. Biol. Chem. 2012, 287, 33873-33882
32. Piscitelli, F.; Ligresti, A.; La Regina, G.; Coluccia, A.; Morera, L.; Allara, M.; Novellino, E.; Di Marzo, V.; Silvestri, R. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB(1) receptor J. Med. Chem. 2012, 55, 5627-5631
33. Mahmoud, M. M.; Ali, H. I.; Ahn, K. H.; Damaraju, A.; Samala, S.; Pulipati, V. K.; Kolluru, S.; Kendall, D. A.; Lu, D. Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1) J. Med. Chem. 2013, 56, 7965-7975
34. Khurana, L.; Ali, H. I.; Olszewska, T.; Ahn, K. H.; Damaraju, A.; Kendall, D. A.; Lu, D. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1) J. Med. Chem. 2014, 57, 3040-3052
35. Stuart, D. R.; Bertrand-Laperle, M.; Burgess, K. M.; Fagnou, K. Indole synthesis via rhodium catalyzed oxidative coupling of acetanilides and internal alkynes J. Am. Chem. Soc. 2008, 130, 16474-16475
36. Perrey, D. A.; German, N. A.; Gilmour, B. P.; Li, J. X.; Harris, D. L.; Thomas, B. F.; Zhang, Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor J. Med. Chem. 2013, 56, 6901-6916
37. Sammakia, T.; Hurley, T. B. Studies on the mechanism of action of 2-formyl-4-pyrrolidinopyridine: isolation and characterization of a reactive intermediate J. Org. Chem. 1999, 64, 4652-4664
38. Tsukamoto, I.; Koshio, H.; Kuramochi, T.; Saitoh, C.; Yanai-Inamura, H.; Kitada-Nozawa, C.; Yamamoto, E.; Yatsu, T.; Shimada, Y.; Sakamoto, S.; Tsukamoto, S. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5 H -1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists Bioorg. Med. Chem. 2009, 17, 3130-3141
39. Handy, S. T.; Zhang, Y.; Bregman, H. A modular synthesis of the lamellarins: total synthesis of lamellarin G trimethyl ether J. Org. Chem. 2004, 69, 2362-2366
40. Handy, S. T.; Zhang, Y. N. Approaches to the synthesis of the lamellarins and related natural products. A review Org. Prep. Proced. Int. 2005, 37, 411-445
41. Zhang, Y.; Gilliam, A.; Maitra, R.; Damaj, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 2010, 53, 7048-7060
42. Fulp, A.; Bortoff, K.; Zhang, Y.; Seltzman, H.; Mathews, J.; Snyder, R.; Fennell, T.; Maitra, R. Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists J. Med. Chem. 2012, 55, 10022-10032
43. Fulp, A.; Bortoff, K.; Seltzman, H.; Zhang, Y.; Mathews, J.; Snyder, R.; Fennell, T.; Maitra, R. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity J. Med. Chem. 2012, 55, 2820-2834